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ACD: Acid Citrate Dextrose
ADP: adenosine diphosphate
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CaCl2: Calcium Chloride
cAMP: Cyclic Adenosine 3’-5’ MonoPhosphate
CHO: Chinese Hamster Ovary
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DTT: Dithiothreitol
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HRP: Horse Radish Peroxidase
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Pal-FF: Palmitylated-KVGFFKR peptide
PE: Phycoerythrin
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PGE-1: Prostaglandin E|
PINCH-1: Particularly interesting new Cys-His protein 1 
PKARla: cAMP dependent P K A la  regulatory subunit 
PMSF: Phenyl Methyl Sulphonyl Fluoride 
PP1: Protein Protein Interaction 
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The pathological role o f platelets in cardiovascular disease is well established. The major 
platelet cell adhesion molecule, am,(33 has been a target for research into anti-thrombotic 
agents. It is a cell-surface cell adhesion molecule belonging to the integrin family and it plays 
a critical role in platelet function. It is present on the plasma membrane o f circulating platelets 
in an inactive or quiescent state. Following vascular injury or thrombotic triggers, it 
‘activates’ by undergoing a profound change o f  conformation. However, little is known about 
the molecular mechanisms underlying this activation. Previous work has identified a 
regulatory sequence (KVGFFKR) within the cytoplasmic tail that controls integrin activation 
(Stephens et al., 1998). Subsequently a number o f novel platelet cytoplasmic proteins were 
discovered that interact with this regulatory region. They include CIB1 (Naik et al., 1997), 
AUP-1 (Kato et al., 2002), PP1 (Vijayan et al., 2004), PP2A (Gushiken et al., 2008), ICln and 
RN181 proteins (Larkin et al., 2004). Recent work by, confirmed all these proteins and also 
identified a number o f  novel platelet proteins that may regulate integrin function by 
competing for binding to the a-integrin regulatory region (Raab et al., 2010). The aims o f  this 
study are to characterize some o f  these proteins and to investigate their capacity to control 
integrin function in human platelets.
The proteins that were chosen for this study are cyclic AMP protein kinase a (regulatory 
subunit; PK A R la) and 2 members o f  LIM protein family: PINCH-1 and the paxillin 
homologue Hic-5.
Western blotting was used to verify the presence o f these proteins in human platelets and to 
examine their capacity to be altered by platelet activation. We demonstrated that platelets 
express all 3 proteins. In addition, I show evidence for activation-dependent modification o f  
these proteins in response to pro-thrombotic stimuli. P K A R la and Hic-5 show evidence o f  
post-translational modification, whereas PINCH-1 shows evidence o f  proteolytic degradation 
in response to platelet activation. Our preliminary evidence (Raab et al., 2010) suggested 
binding o f  PK A R la, PINCH-1 and Hic-5 to the integrin anbP3 via a m otif in the platelet 
membrane. However not all those findings were consistent with the results that we got. By 
using co-immunoprecipitation we found that the proteins PK A R la and PINCH-1 do not bind 
with the integrin directly. On the other hand, our observations for Hic-5 suggest that it may be 
a novel integrin regulating protein.
Abstract
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C h a p t e r  1
G e n e r a l  I n t r o d u c t i o n
Platelets are anucleate blood cells that have discoid shape and a life-span o f 7-9 days. They 
perform a regulatory role in haemostasis and are targets for drug action in cardiovascular or 
thrombotic disease. Platelets become activated when they adhere to damaged blood vessels. 
During activation they release biomolecules from either the dense or alpha-granules, such as 
adenosine diphosphate (ADP), calcium and fibrinogen. In addition, platelet activation results 
in the activation o f the platelet-specific receptor anb(33 that belongs to the integrin family. 
Integrins are cysteine-rich heterodimeric molecules that alter their affinity for ligands in 
response to cellular activation (O'Neill et al., 2000). The integrin is an abundant platelet 
cell-surface adhesion molecule and plays a critical role in platelet function. However, the 
exact intracellular mechanism o f  integrin activation is not fully understood. The integrin 01^ 3 
is present on the plasma membrane o f  circulating platelets in an inactive or quiescent state 
(Hynes, 2002). The integrin anbP3 (also termed GpIIb/IIIa) is composed o f two separate 
protein subunits, the alpha (a) subunit a^, and the beta (P) subunit P3. The a-subunit is made 
o f  a heavy and a light chain that are connected by a disulphide bonds. It has a conserved motif 
989KxGFFKR995 in the cytoplasmic region that was characterized in a previous study 
(Stephens et al., 1998). A  cell-permeable peptide corresponding to this m otif activates 
integrins in platelets, suggesting that this m otif plays a pivotal role in integrin activation 
(Stephens et al., 1998).
Several studies that were conducted in our laboratory investigated the interaction o f  
cytoplasmic proteins with the platelet integrin aubP3 in the expectation that a molecular 
mechanism for integrin activation would emerge. We hypothesise that the integrin tail o f anb 
regulates the signalling cascade in platelet by modulating the interaction o f  cytoplasmic and 
cytoskeletal proteins. To know more about the proteins and interactions, a study was designed 
to explore the nature o f  platelet proteins that bound to the integrin cytoplasmic tail in resting 
and activated platelets (Daxecker et al., 2008); (Raab et al., 2010). Three scientific methods 
were used in these studies to detect and characterise new proteins: ( 1) peptide affinity 
chromatography using the conserved 989KVGFFKR995 motif, (2) LC-MS/MS to identify 
bound platelet proteins and (3) protein chips to detect novel proteins that had an affinity for 
KVGFFKR using information obtained from protein:protein interaction (PPI) databases.
In the studies by Raab and Daxecker, they immobilized the critical, conserved 
989KVGFFKR995 peptide onto an inert bead that could then be used as an affinity matrix, as 
illustrated in Figure 1.1 A-C. Platelet lysates prepared from resting or activated platelets were
allowed to interact with the column before being eluted with Guanidium HC1 (Figure 1.1D). 
The eluted peaks were separated on SDS-PAGE (Figure 1.1E) and excised for analysis by 
liquid chromatography-tandem mass spectrometry (LC-MS/MS). The eluted proteins were 
identified from their mass spectra using the GPM (Global Proteome Machine) online 
resource.
Figure 1.1: A-C show the sequence of synthesising the peptide affinity column. D is a chromatogram 
of human platelet lysate with proteins that bind to the KVGFFKR motif which are retained by the 
peptide affinity column. Below the chromatogram, sample dot-bots for the presence of ICln, RN181 
(previously known as MASY), CIB-1, PPI, AUP-1, integrin p3, TIM and COX1 are shown. E is an 
SDS-PAGE analysis of proteins from resting or activated sonicated platelet lysates (SPL) that were 
separated on the peptide affinity chromatography. Peaks 1, 2 and 3 correspond to the observed peaks 
eluted from the column and labelled in the chromatogram in D (Raab et al., 2010).
It was discovered that all previously identified integrin-binding proteins including CIB1 (Naik 
et al., 1997), AUP-1 (Kato et al., 2002), PPI (Vijayan et al., 2004), PP2A (Gushiken et al., 
2008), ICln and RN181 proteins (Larkin et al., 2004) bound to the integrin anb cytoplasmic 
m otif as outlined in Table 1.1. 38 additional platelet proteins were bound to the peptide 
affinity chromatography column and identified by LC-MS/MS, but it is not certain if  these are 
specific interactors or non-specific interactors. Some proteins were abundant in the platelet 
lysate but not in the peptide column eluate (such as Vinculin). Other proteins were the 
opposite i.e. abundant in the column eluate but not in the platelet lysate (Raab et al., 2010).
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These proteins are candidates as novel integrin-regulating proteins.
Proteins enriched on peptide column
HlC-ff ARAÖ5 043204
actlrt-lke protein 017421 
TUBULIN BETA-5
Latent-TOF beta-binding protein Q147B6
Placental ribonuclease inhibitor
Tripeptidyl-pepiidase 1 014773
Calcium and integrin-binding protein 1Q99B28
143-3 protein epsilonPB229B
Dynactin subunit3 mplex subunit 22 075835
Alpha-actlnin-2 P35609
Myosin light ohain SB UniProtKB/P 14649
Ubiquitin oarboxyl-terminal hydrolase 5 P4SQ74
Cathepsin A
cAMP-dependentPKArl P10644
Filamin- A  075369
Tropomyosin P07S51
Ser/Thr phosphatase 2A catalytic P62714
HEAT SHOCK-RELATED 70 KDA PROTEIN
G- protein © beta subunit 2 P62879
Ras-related protein Rab-6A40
Ser/Thr phosphatase PP1-gamma cat P36873
0- protein Galpha P50148
Myosin regulatory light chain MRLC3 P19105
Tubulin alpha-2 Q13748
Aotin- related protein 2/3 comp lex 41k Da 015143
ATP synthase subunit alpha P25705
T- complex protein 1 thetaP50990
Talin-2 Q9Y4Ö6
WD repeat protein 1 075063
Bridging integrator 2 er-associate Q9UBW5
Beta-parvinQ9HBI1
PINCH-1 F48059
Talin-1 Ü9Y490
Multimerin-1 Q13201
I nte gr ir> link ed p rote in k i nas e Q13418
E F100
81
81
49
49
49
36
36
36
25
25
25
18
25
14
14111111
9
9
5
5
5
5
4
4
4
3
3
32222
Table 1.1: Proteins Enriched in Peptide Column
38 proteins were identified in eluates from Resting or Activated platelets which bound to the 
KVGFFKR-peptide column. The data shown is peptide values (color coded from yellow (low) to red 
(high) depending on protein abundance) from 5 experiments for resting platelets, 4 separate 
experiments for activated platelets and 10 separate platelet lysates. In some cases, these proteins were 
low abundance proteins which were not observed in platelet lysates (Black). The enrichment ratio was 
calculated as described in the methods section. The known integrin binding proteins CIB1 and protein 
phosphatases are color coded yellow. The proteins selected for this study are highlighted in orange.
They include PK A R la, PINCH-1 and Hic-5. These three proteins were chosen for further 
study because they represent three different levels o f  enrichment and abundance: Hic-5 is the 
most highly enriched o f all the proteins observed in our experiment. In fact, it is higher than 
the previously identified integrin-binding proteins CIB-1 and protein phosphatases 1 & 2. 
P K A R la  appears to be enriched in activated platelets, even though it is only observed in 3 
out o f  9 o f  our affinity experiment. Neither Hic-5 nor P K A R la  are ever observed in platelet 
lysates, suggesting that these are low-abundance proteins. Finally, PINCH-1 is selected, 
because it is always observed at higher intensity in affinity extracts than in lysates. It is an
hVGFFKR Ailing Eitracti
P lie le *  l y s i e s  1-10
Acflvafed
abundant platelet protein that is usually observed in a complex with Parvin and integrin linked 
kinase (ILK). However, despite it being an abundant protein in platelet lysates, we considered 
it interesting because it was always enriched in our affinity extracts. In addition, Parvin and 
integrin linked kinase, its co-associated proteins, were both also enriched in our samples.
The MS analysis techniques that were used have a percentage o f  error associated with them. 
Thus proteins might be observed in the affinity extracts even if  they do not regulate integrin 
function. This may be because they are abundant proteins and are difficult to remove from our 
samples. Alternatively, they may be ‘sticky’ proteins with high levels o f  charge and/or 
hydrophobicity permitting them to adhere to complementary regions on our peptide affinity 
column. Finally, proteins may bind indirectly to the integrin regulatory region, via another 
directly-binding protein. We have represented this argument in Figure 1.2 below.
We believe that the proteins exist in platelets in four different states relative to integrin 
function. A  protein that adheres to the integrin in the resting platelet state is termed ‘X ’. A  
protein that adheres to the integrin in the activated platelets only is termed ‘Y ’. A  protein that 
binds to the integrin regardless o f  its activation status is called ‘Z’. Finally, the last protein is 
one that does not bind to the integrin at all and is referred to as ‘W ’. In this thesis, I will 
attempt to define which category PK A R la, PINCH-1 and Hic-5 proteins belong to.
10
Figure 1.2: Model of protein binding to integrin cytoplasmic tail
In order to confirm the MS data and confirm if  the observed binding is significant, our study 
aims to verify that the proteins PKARIa, PINCH-1 and Hic-5 are present in platelets using 
western blotting technique. Then w e w ill verify whether the proteins are associated directly 
with the integrin anb(33 by using co-immunoprecipitation technique. Finally, we will determine 
for each protein which definition they conform to in the X, Y, Z and W definition above. To 
date, little is known about PK ARIa and PINCH-1 in platelets. On the contrary, Hic-5 has 
been mentioned in the literature but its role in integrin regulation is uncertain.
cAMP-dependent PK A R Ia
The second messenger cAMP controls inside-out signaling pathways such as regulating 
metabolism and proliferation. cAMP-dependent protein kinase-A (PKA) holoenzyme has a 
tetrameric structure. It has two regulatory (R) and two catalytic (C) subunits (Bossis and 
Stratakis, 2004). cAMP levels are elevated by inhibitors o f  platelet activation such as the 
endothelial-derived prostaglandin (PG) I2. PG I2 is released constantly by intact endothelial 
cells and interacts with PG I2 receptors on the platelet surface. On activation o f these 
receptors, platelets respond by elevating intracellular cAMP levels. This inhibits or modulates 
the ability o f  the platelets to activate.
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In the presence o f cAMP, the holoenzyme o f  PKA breaks down into a dimer o f regulatory 
subunits and 2 free catalytic subunits. Both subunits have multiple isoforms: a, p and T  o f  
types I and II. P K A R la  enzyme corresponds to the regulatory subunit (R) o f  type la . There 
are four types o f the regulatory subunit R la , R ip , R2a and R2p. The isozymes (a  and P) o f  
regulatory subunit 1 o f  protein Kinase A exist in human neoplastic B cell line (Reh) (Tasken 
et al., 1993). P K A R la  was first discovered in platelets by our research group (Raab et al., 
2010). The regulatory subunit is the major component o f type I o f  PKA that controls serine- 
threonine kinase activity (Bossis and Stratakis, 2004).
PINCH-1 (LIM S1)
This particularly interesting new Cys-His protein 1 (PINCH-1) is also referred to as LIMS1. 
PINCH-1 is a cytoplasmic protein that is composed o f  5 LIM domains. LIM domain is a 
double-zinc finger m otif unit that is found in many proteins (Dawid et al., 1998). 
Theoretically, PINCH-1 binds to Hic-5 (TGFB1I1) by the LIM zinc-binding 5 domain (The 
Universal Protein Resource). PINCH-1 has a role in cell differentiation and proliferation. It 
also forms a complex with integrin-linked kinase (ILK) and Parvin (Stanchi et al., 2009). 
PINCHl-ILK-Parvin molecules create a complex called IPP. Both PINCH-1 and ILK are 
important in forming this complex and the removal o f either o f  these for any reason affects 
the down regulation o f  the proteins (Stanchi et al., 2009). In the Raab study, all 3 components 
o f  this complex were observed to be enriched in the affinity column eluates, suggesting that 
this complex binds to the platelet alpha integrin cytoplasmic tail (Raab et al., 2010). The 
intensity o f binding for each individual protein was always greater in resting than in activated 
platelets. We therefore decided to study PINCH-1 protein because it forms an important 
complex with ILK and Parvin and may play a role in integrin activation.
Hic-5 (TGFB1I1)
Hic-5 is the only member o f paxillin family in human platelets (Osada et al., 2001). It is a 
cytoskeletal protein with 4 LIM domains at the carboxy terminal (Hagmann et al., 1998). 
TGFB1I1 is the abbreviation o f  the genetic name: transforming growth factor beta-1-induced 
transcript 1 (The Universal Protein Resource). It regulates protein interactions and presents in 
the focal adhesion points in the cells. Hic-5 in activated platelets is tyrosine phosphorylated 
and negatively regulates platelets aggregation (Rathore et al., 2007). Hic-5 binds to different a 
integrin tails and regulates their function (Liu et al., 1999). However, (Liu et al., 1999) also
12
showed that I Iic-5 protein does not appear to bind to «Mb- In contrast, however, it was found 
by our group that IIic-5 binds to the integrin chain-aiib regulatory peptide in a chromatography 
column (Raab et al., 2010). We therefore studied the role o f  IIic-5 as a potential integrin- 
regulatory protein in activated platelets.
The future plan is to find out the precise molecular effects of the novel proteins on the 
integrin’s cytoplasmic domain in order to better understand the choreography of signalling 
proteins that co-ordinate integrin activation in response to prothrombotic signals.
13
C h a p t e r  2
M a t e r i a l s  a n d  M e t h o d s
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2.1 Materials
2.1.1 Equipments and Reagents
A ll chemicals and products were obtained at highest grade possible and were from Sigma- 
Aldrich (UK), except where specifically mentioned below. Thrombin receptor activating 
peptide (TRAP: SFLLRN) was obtained from Bachem Distribution Services GMBH- 
Germany. Palmitylated KVGFFKR peptide was custom synthesized by JPT Peptide 
Technologies, Germany. Octyl-a/ß-Glucoside was obtained from Fluka Analytical- 
Switzerland, Halt ™  Protease Inhibitor Cocktail and Phosphatase Inhibitors were from 
Thermo Scientific, (Rockford, U.S.A.). Protein G-Sepharose 4 fast was from GE Healthcare, 
UK. SuperSignal® West Pico Chemilumiscent Substrate is obtained from Thermo Scientific, 
UK.
2.1.2 Antibodies
2.1.2.1 Prim ary Antibodies
The following primary antibodies were obtained from Santa Cruz Bio-Technology (SCBT) 
company, Inc.-(Germany) except where specifically mentioned below.
Table 2.1.
Target
Protein Source
Supplier’s
SCBT
(code)
Details Dilution for WB
Predicted 
Molecular 
weight of 
the protein
Anti-
PKARla
Mouse
monoclonal 3546C2a
Raised against recombinant 
protein corresponding to a 
region near N-terminus of 
PKAla regulatoiy of 
human origin
1: 100- 
1:1000 48kDa
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Anti-
PKARla
Goat
polyclonal C-14
Affinity purified antibody 
against a peptide mapping 
within an internal region of 
PKAla regulatory of 
human origin
1:200 48kDa
Anti-
PINCH-I
Goat
polyclonal D-18
Affinity purified antibody 
against a peptide mapping 
within an internal region of 
human origin
1:200-
1:1000
37kDa
anti-Hic-5 Mousemonoclonal F6
Raised against amino acids 
1*75 mapping at the N- 
terminus of human Hic-5 
origin
1:100-
1:500 55kDa
anti-Hic-5 Rabbitpolyclonal H75
Raised against amino acids 
1-75 mapping at the N- 
terminus of Hic-5 of 
human origin
1:200 55kDa
anti-Hic-5 Mousemonoclonal
Clone 34 
(#611165)
Mouse IgG|, from BD 
Transduction Laboratories 1:500 55kDa
anti-
Integrin
allb
(SZ.22)
Mouse
monoclonal SZ.22
Raised against washed 
human platelets. Initial 
batches from SCBT; 
subsequent batches from 
Beckman Coulter-Co 
Clare-Ireland. At 128kDa
1:200 - 
1:10,000
137kDa
anti-GPIb
(CD42b)
Goat
polyclonal C-20
Raised against a peptide 
mapping at the C-terminus 
of human Gplb
1:500 143kDa
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2.1.2.2 Control IgG Antibodies
Antibodies that have been used as controls in immunoprécipitation are normal mouse IgG: sc- 
2025 and normal rabbit IgG: sc-2027.
2.1.2.3 Secondary Antibodies
Rabbit anti-goat IgG-HRP (SC-2922) was obtained from SCBT. Goat anti-rabbit IgG-HRP 
(#31460) was obtained from Pierce Immunopure®, Thermo Scientific. Goat anti-mouse IgGi 
was obtained from Beckman Coulter-USA. Secondary antibody dilutions were varied 
according to optimised experiments and are indicated in Figure legends.
2.2 Methods
2.2.1 Washed platelets preparation
Venous blood was drawn from healthy volunteers who had not taken aspirin or other non­
steroidal anti-inflammatory drugs for the preceding 10 days, according to approved protocol 
by the Royal College o f  Surgeons in Ireland Research Ethics Committee. Washed platelets 
were prepared as described (Stephens et al., 1998). Briefly, this involved the anti-coagulation 
o f  blood with 15% (v/v) acid-citrate-dextrose (ACD) (38mM citric acid anhydrous, 75mM  
sodium citrate, 124mM dextrose). Blood was centrifuged at 150 x g for 10 minutes and the 
platelet rich plasma (PRP), the top fraction, was transferred to a separate tube using a plastic 
transfer pipette. PRP was acidified with ACD to pH 6.5 and lpM  prostaglandin Ei (PGEi) 
was added. The platelets were pelleted at 720 x g for 10 minutes and resuspended in JNL 
buffer (6mM dextrose, 130mM NaCl, 9mM Na Bicarbonate, lOmM Na Citrate, lOmM Tris, 
3mM KC1, 0 .8 ImM KH2PO4, 0.9mM MgCl26H20  pH 7.35). The platelet count was adjusted 
to 3 x l0 5 platelets/pl. Washed platelets (WP) were diluted either to 6x10'Vfil for western 
blotting or higher for co-immunoprecipitation and were supplemented with 1.8mM CaCl2 
immediately prior to use. Platelet count was estimated by analyzing samples on a Sysmex 
automatic blood analyzer, (Sysm ex KX Series, SYSMEX UK LTD-Milton Keynes, MK8 
8DF, England, United Kingdom).
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2.2.2 Platelet aggregation
Platelet Aggregation was performed at 37°C in a Platelet Aggregation Profiler (BioData PAP- 
4) (Horsham-USA). Thrombin receptor activating peptide (TRAP) was used as an agonist for 
platelet aggregation. Pal-KVGFFKR was also used to activate washed platelets. Washed 
platelets were equilibrated in the aggregometer at 37°C before the addition of agonists. 
Platelet aggregations were followed for three minutes. Three washed platelet samples were 
prepared for each western blotting analysis. The first sample was stirred for 3 minutes in the 
aggregometer in the absence of an agonist as a negative control. This sample is referred to as 
“resting platelets”. The second sample was treated with TRAP at a final concentration of 
10(iM, to maximally stimulate platelet aggregation. The third sample was partially activated 
by the integrin-derived palmitylated peptide at a concentration of 100(aM. After 3 minutes in 
the aggregometer, the samples were lysed on ice using a lOx lysis buffer (0.5mM Octyl-a/p- 
Glucoside, lOmM PMSF, 20mM Tris pH 7.4, 0.1% Triton-X-100, 50mM EDTA, 5X Halt ™ 
Protease Inhibitor Cocktail and 10X Phosphatase Inhibitors in JNL buffer) to dissolve 
platelets membrane and stop any protease activities in the platelets. Samples were vortexed 
every 10 minutes for an hour to ensure full solubilization of all protein in the sample, and then 
spun to precipitate any insoluble residues. Samples are either frozen at -80°C until required 
for analysis, or were used immediately. A Bradford assay was used to determine the protein 
concentration in each sample.
2.2.3 Bradford Assay
Platelet lysate samples are analyzed for protein concentration using the DC Protein Assay 
from Bio-Rad Corporation. 5pl of samples were loaded in triplets into a 96 well plate that can 
be read by Wallac plate reader (WallacVictor2TM) 1420 Multilabel Counter. Serial dilutions of 
bovine serum albumin (BSA) in IX lysis buffer were prepared to generate a BSA standard 
curve from 0 -  1.5mg/ml. Reagents A’ and B were added to the samples in the wells 
according to the manufacturer’s instructions. After an incubation of 15 minutes the 
absorbance of the samples in the plate were read at 750nm according to the manufacturer’s 
instructions. The concentration of protein in the platelet lysate samples could then be deduced 
from the standard curve.
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2.2.4 Samples preparation for immuno-detection
Frozen human platelet lysates samples were thawed in an ice-bath and mixed with 2X sample 
buffer at a ratio of 1:1.
2X Sample Buffer (pH 6.8) is composed of: 0.5M Tris base, 4% SDS, 75mM DTT, 2.17M 
Glycerol, 0.01% Bromphenol Blue. Samples were heated at 95°C for 3 minutes and spun for 1 
minute in a mini Spectrafuge that was purchased from Labnet International, Inc. to precipitate 
any impurities before loading onto SDS-poly-acrylamide gels. In initial experiments, lysates 
were divided into 2 groups; the first group contains three previously prepared samples that are 
treated with a reducing sample buffer containing DTT, and the other group is treated with a 
2X non-reducing sample buffer pH 6.8 that does not contain DTT (0.5M Tris base, 4% SDS, 
2.17M Glycerol, 0.01% Bromphenol Blue). In the case of immunoprécipitation experiments, 
samples were treated with only reducing sample buffer.
2.2.5 Immunoprécipitation
Two protocols were used to optimise the experimental conditions and both gave same results. 
The first protocol that was used is from SCBT Company and the second is from the 
University of Melbourne (UM) for immunoprécipitation of platelet proteins.
2.2.5.1 Immunoprécipitation according to method A (SCBT)
Protein G-sepharose beads were used when immunoprecipitating with monoclonal antibody. 
The beads were washed 3 times from slurry with ice-cold high-salt (hs) TBST (150mM NaCl, 
20mM Tris, pH 7.4, 0.1% Tween 20) and incubated rotating for 30 minutes at 4°C with 1ml 
(~600xl 03/ul) platelet lysates and 0.25ug/ml of IgG-control antibody from the same species of 
the primary antibody. The precleared lysate mix was spun and the supernatant retained for the 
next step. The pelleted beads were washed 5 times with ice-cold TBST (hs) IX, and eluted 
with 2X sample buffer. This sample is called the ‘negative control’ or IgG sample. All steps 
were performed at 4°C. The supernatant was transferred to a fresh eppendorf and incubated 
with the required immunoprécipitation antibody (0.2-2ug/ml) for 1-2 hours rotating at 4°C. 
Freshly washed beads of approximately (25ul/lane) were then added to the 
supernatant/antibody mix and incubated over night rotating at 4°C. The next day the beads 
were pelleted and washed 5 times with ice-cold hs TBST and eluted with 2X sample buffer. 
This sample is called the ‘IP sample’ and represents the specific immunoprecipitated fraction.
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2.2.52 Immunoprécipitation according to Method B (UM)
Protein A-Agarose beads were used to immunoprecipitate with polyclonal antibodies. The 
beads were washed 3 times from slurry with ice-cold PBS and incubated rotating for 1 hour at 
4°C with 0.5ml (~600xl03/ul) platelet lysates for preclearing. The platelet lysate was 
microfuged briefly to pellet the beads (72g for 30 seconds). The supernatant was divided into 
two and removed to fresh cppendorfs. The first eppendorf is the negative control which is 
incubated with an IgG-antibody and the second is for the pull-down which is incubated with 
the immunoprécipitation antibody. Both antibodies added for incubation of equal amounts 
(5ug/500ul), rotating at 4°C from 2 hours to overnight. Then equal amounts (25ul/lane) of 
fresh washed beads were added to both eppendorfs and kept rotating for 1-2 hours at 4°C. 
After that, the beads were pelleted gently and washed 3 times with PBS, eluted with 2X 
sample buffer, boiled and spun. Samples were ready for use.
2.2.6 Immunoblotting
SDS-PAGE: Sodium Dodecyle Sulfate-PolyAcrylamide Gel Electrophoresis was performed
according to standard procedures (Laemmli, 1970). 10% (#25221) and 4-20% gradient
(#25224) Precise protein gels were obtained commercially from Fisher Thermo Scientific
(PIERCE)-IJ.K. Prepared samples were loaded onto the 10% or gradient gels. Samples were
run at a constant voltage as follows: 60V for 20 minutes then 100V for 1 hour, in a IX
running buffer (25mM Tris, 192mM Glycine, 0.1% SDS). After that the gel was finished
running, a mini Trans-Blot Cell was assembled by placing the gel against a polyvinylidene
fluoride (PVDF, transferring membrane that is immersed for 3 minutes in methanol before
putting it in the sandwich) between nylon pads and blotting papers to form a sandwich (the
nylon pads, blotting papers and transferring membrane were soaked in a transferring buffer
prior to preparing the sandwich). Transfer is achieved by applying a constant voltage (100V)
to drive the proteins from the gel onto the PVDF in a BIO-RAD blotting tank for 1 hour. For
this purpose, a IX transfer buffer is prepared from a 10X stock (250mM Tris, 1.92M Glycine,
0.2% SDS). One volume of lOx transferring buffer is diluted with 2 volumes of methanol in
dH^O. After transfer, the membrane was removed from the sandwich and is blocked with 5%
of either BSA (Bovine serum albumin ) or 5% milk powder in 0.1% Tween20 in TBS (TBST:
20mM Tris Base, 137mM NaCl pH7.4) for one hour at room temperatre. Three washes for 10
minutes for each blot were done using TBST. The blots were then incubated over night with a
primary antibody at 4°C at the dilution indicated in the Table 1 above. The next morning after
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washing the blots three times for 10 minutes for each blot, they were incubated with a 
secondary antibody for 1- 2 hours rotating at room temperature. A number of different 
secondary antibody dilutions were used during the course of western blotting. The dilutions 
that were routinely used are 1:50,000 for anti-mouse, 1:10,000 for anti- goat and for anti­
rabbit. The membranes were washed again three times for 10 minutes each using IX TBST. 
Membranes were exposed to SuperSignal® West Pico Chemilumiscent Substrate for 5 
minutes to detect the antibodies. The blots were visualised by either UVP WorkLS software 
or by developing images using Kodak Biomax XAR film that was obtained from Sigma 
Aldrich IRL in the dark room. Each western blot was performed in pairs: one blot was 
incubated with the immunoprecipitating antibody allb (SZ.22) as a control and the second 
was incubated with one of the primary antibodies against the novel proteins. Often, the blots 
were reprobed with the opposing antibody to verify results. At least 4 separate western blots 
on separate donors were performed for each antibody, as indicated in the Figure legends.
2.2.7 Normalising Bands
The band’s intensity was determined using UVP imaging system (Vision WORKsLS) and 
ImageJ software for all western blots. The bands intensity was normalized to all samples’ 
bands in the experiment. Thus the total intensity of the western blot bands was summed for 
the 9 lanes on each gel. This was assigned a value of 100. Each band was expressed as a 
percentage of this total. In this way, the variance between experiments was minimized.
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C h a p t e r  3
O p t i m i z i n g  W e s t e r n  B l o t t i n g  C o n d i t i o n s
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The aim of this chapter is to optimize the experimental conditions for western blot analysis 
and to discuss the characterization of the proteins of interest. In this study we focused on 
PKARla, PINCH-1 and Hic-5 proteins in platelet lysates. In order to identify if there are any 
protein modifications upon cellular activation, we sought to identify suitable antibodies to 
detect these proteins. Throughout this chapter, problems arising during western blotting will 
be discussed.
3.1 Introduction
The basic theory of western blotting technique is that cellular proteins can be separated by 
SDS-PAGE and transferred to a nitrocellulose or PVDF membrane that can be probed by 
specific antibodies for the protein of interest. The primary antibody binds spcifically to the 
protein from the platelet lysates on the western blot membrane. The primary antibodyis 
detected by an appropriate secondary antibody that is coupled to a detection system.
Good western blots should reveal a band that shows a strong signal on a clear background. 
The position of the band should correspond to the predicted molecular weight of the protein 
of interest by comparison to molecular weight standards. Good protein bands should appear as 
a straight line. Sometimes a protein band is detected at a molecular weight that is slightly 
different from the predicted molecular weight for the reasons described below.
There are a number of crucial aspects that can influence the results of western blotting: 
choosing the correct gel percentage, chosing an appropriate antibody and preparing the 
buffers at the correct pH. In addition, background staining and non-pecific binding can be 
reduced by inclusion of various reagents in the wash buffers, altering the blocking agent, 
blocking for longer periods of time and including high-salt or detergents in the wash buffers.
3.1.1 Chosing the right gel percentage
SDS Poly-Acrylamide Gels can be prepared with varying percentages of polymeric 
acrylamides, usually 5% to 20%. The percentage of the gel should be chosen according to the 
molecular weight of the protein of interest. The relationship between the molecular weight or 
size of the protein and the gel percentage is inversely proportional, so that high molecular 
weight proteins (> 100 kDa) will separate poorly in a high percentage gel (15%) but will 
separate with greater resolution in a lower percentage gel (7%). Thus low molecular weight 
proteins resolve better on high percentage gel. SDS is a denaturing detergent that is negatively
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charged. When proteins bind to SDS they denature and travel vertically through the gel and 
separate according to their charge. However, most proteins are charged at the pH of SDS- 
PAGE running gel, (pH 8.8) and the charge is proportional to their size. Proteins therefore 
separate in SDS polyacrylamide gels according to thier size, from the highest weight to the 
lowest.
3.1.2 Selecting an Appropriate Antibody
Antibodies are one of the most abundant research tools that are used in analytical methods 
such as western blotting, co-immunoprecipitation and enzyme-linked immunosorbent assays 
(ELISA). To have a validated antibody, it must be specific, selective and have reproducible 
profile for its purpose. The definition of antibody validation by the food and drug agency 
(FDA) is “the process of demonstrating through the use of specific laboratory investigations, 
that the performance characteristics of an analytical method are suitable for its intended 
analytical use”. Therefore, choosing a good antibody can be done either by the selection of a 
commercial antibody and testing it in the laboratory or by checking previous publications that 
investigate the protein of interest (Bordeaux et a l, 2010). If the antibody is chosen from 
commercial suppliers without the benifit of support from published literature, then the 
available datasheets should be examined carefully. If the antibody is chosen from published 
literature, then it is important to compare initial results with those that are published. Usually, 
we can expect to observe a single band at a certain molecular weight that corresponds to a 
single protein in a cellular lysate. However, the presence of a doublet can be due to several 
reasons such as post-translational modification by phosphorylation or ubiquitination (Raab et 
al., 2010).
3.2 Results
For the purposes of this study, we investigated the presence of three proteins found in human 
platelets. The proteins are cAMP-dependent PKA-regulatory subunit (PKARla), particularly 
interesting new Cys-His protein 1 (PINCH-1) and a paxillin homolog (Hic-5). We sought to 
examine changes of expression of these proteins upon platelet activation. Therefore, western 
blotting analysis using specific antibodies was utilised in order to look at their presence in 
platelets. To date, little is known about PK A R la and PINCH-1 proteins particularly in 
platelets and there are no conclusive publications regarding them. Therefore, the knowledge 
of appropriate antibodies for use in western blotting was not available in the literature.
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However, the presence of Hic-5 in platelets is mentioned in the literature (Hagmann et al., 
1998); (Osada et al., 2001). In order to identify suitable antibodies for use in platelet studies, 
we examined expression of each protein with selected antibodies using western blotting 
technique. We were able to select antibodies for Hic-5 from the published literature. 
However, we had to use our instincts for the choice of antibodies for PINCH-1 and PKARla.
Washed platelets samples were used in all western blot experiments. Lysates from three 
different platelet preparations were prepared as follow: (1) Platelets that were kept quiescent 
or “resting”; (2) Platelets that were maximally activated using thrombin receptor activating 
peptide (TRAP) using conditions that are well-established in the literature, and (3) platelets 
that were partially activated by the integrin-derived palmitylated peptide (KVGFFKR), as 
previously described by our group (Stephens et al., 1998); (Bernard et al., 2009) . Two sets of 
conditions were used to prepare the platelet lysates for electrophoresis: reduced and non­
reduced; wherein thiol bonds responsible for the protein secondary structure are left intact 
(non-reduced) or the samples are subjected to a reducing chemical environment with 
dithiothreitol (DTT).
All primary antibodies were bought from the commercial company SCBT in Germany except 
where mentioned.
3.2.1 Identification of PKARla in human platelets
Western blot experiments were done to detect the presence of PKA Rla protein in human 
platelets. Two different antibody clones were purchased from Santa Cruz Biotechnology 
(SCBT) (3546C2a: Sc-81641) (PKARla, SCBT-b) and (C-14: sc-18800) (PKARla, SCBT- 
a).
The preliminary experiments identified that the first antibody 3546C2a was not adequate in 
detecting the protein. The bands obtained from the western blots from this antibody were faint 
and not clear. They were observed as faint bands at approximately 48kDa, as seen in Figure
3.1 A. In order to improve detection, we used different series of dilutions of the antibody 
(Figures 3.1 A and 3.IB). In addition, we used two experimental conditions: reduced and non­
reduced samples.
In all experiments, the bands detected were weak or absent. Additional changes were done to 
improve the band’s detection such as using higher gel percentage, adjusting antibody’s
25
dilutions and loading higher protein concentration (data not shown). Regardless of all the 
introduced changes (Figures 3.1 A and 3.IB), blots continued to be vague, and non- 
reproducible leading us to the conclusion that either PK A R la is not present in human 
platelets or that the 3546C2a antibody is not suitable for use in my assays. As a result, 
replacing the antibody’s batch, form or brand was the next step.
A second antibody PKARla(C-14): sc-18800 was therefore selected. It was sourced and 
proved to be better. The bands were darker producing a strong signal on a bright background. 
C-14 is a polyclonal antibody. Polyclonal antibodies recognize more epitopes on the target 
protein than monoclonal antibodies and we showed that this antibody gives the expected 
results. The bands were more constant at the expected molecular weight (Figure 3.1C and 
3.ID). Protein bands were clearer and more intense than with the first PK A R la antibody 
(3546C2a). They were easily identified and distinguishable from the background. All blots 
gave the same result. Therefore, this antibody is selective and reproducible.
PK A R la protein is expressed in human platelets and is altered by platelet activation (Figure 
3.ID). Although the expected molecular weight of PKARla is 48kDa, we consistently 
observed doublet at 48kDa and 55kDa under reducing conditions. The bands observed in 
resting or activated samples of platelet lysate are different in intensity. Using the UVP 
imaging system, the maximum intensity of each band was measured (Figure 3.2).
The intensity of the upper band (55kDa) in TRAP-activated platelet lysate (corresponding to 
the sample labelled as S2 in Figure 3.1) is the highest followed by Pal-FF activated platelet 
lysate (S3) and then resting platelet lysate (SI). This was seen in 5 independent experiments 
(Figure 3.2). Moreover, western blots showed that bands’ intensity is greatest upon treatment 
with TRAP and Pal-FF peptide. This was found also in PKARla lower band (48kDa); TRAP- 
activated (S2) has the greatest intensity followed by Pal-FF activated (S3) and resting 
platelets (SI).
The band intensity of the 55kDa is 4.54% of the total intensity percentage (100) of the 48kDa 
band in the resting platelet lysates. In contrast, following platelet activation by TRAP, the 
intensity increased to 11.15% of the intensity of the total PKARla protein in this sample, 
suggesting that an activation-dependent modification occurred which resulted in increasing 
the molecular weight of PK A R la from 48kDa to 55kDa.
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Thus, we have shown that PK A R la exists in platelets in one or two isoforms with a 
molecular weight of 48 or 55 kDa and varies in intensity following platelet activation with 
TRAP. The antibody (3546C2a) was of insufficient quality to allow detection of this protein 
in platelet lysates, but a second antibody (C-14) proved to be a better choice.
PKARla protein is a thiol-dependent tetrametic complex. The predicted molecular weight of 
the PKA tetramer that is comprised of two regulatory and two catalytic subunits (Bossis and 
Stratakis, 2004) is 160kDa (The Universal Protein Resource). Dithiothreitol (DTT) is a thiol- 
reducing reagent. Most of our experiments use DTT-treatment prior to SDS-PAGE sample 
separation to allow detection of the specific PK A R la subunit.
In some experiments, we analysed non-reduced samples. Results in these experiments showed 
that when not adding the reducing reagent DTT to the samples, bonds remain intact and bands 
were observed at high molecular weight 160kDa, as seen in Figure 3.1C. This confirms that 
the protein being identified in western blots is indeed the PKARla protein as it is located at 
48/55kDa when gels run under reducing conditions but is located at 160kDa when gels were 
run under non-reducing conditions. 48/55kDa is consistant with the expected molecular 
weight for the PK A Rla monomer, whereas 160kDa is consistant with the identification of a 
tetramer.
In conclusion, PK A R la presents as doublet in western blots of human platelets (n=5). The 
difference in the relative band intensities for the 48kDa and the 55kDa components show 
activation induced changes. Moreover, chosing the suitable antibody, gel percentage and 
working techniques produce a clean western blot.
3.2.2 PINCH-1-Identification of PINCH-1 (LIMS1) in human platelets
The antibody (D-18: sc-47912) was used to probe for PINCH-1 in human platelet lysates, 
(PINCH-1, SCBT). This antibody is new in research as there are no previous publications 
using it. Therefore, we looked at the supplied data sheet from the company and found it to 
have good reactive components. The band illustrated was dense with a good intensity on a 
bright background, thus we acquired the anitbody.
PINCH-1 reactive bands were found in washed platelet lysates. Western blot experiments 
showed PINCH-1 protein a single bands at a molecular weight of approximately 37kDa (n=6) 
as seen in Figure 3.3. In order to improve protein detection we had to increase protein loading
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concentration up to 20 ng per lane. The bands looked defined on a bright background. We 
consistantly got bands with different intensities: The resting platelet lysate band was the most 
intense band, then the Pal-FF activated sample and the least intense was the TRAP-activated 
sample. This was observed in 6 separate experiments as demonstrated by the densitometry 
data in Figure 3.3C. The reason behind low band intensity is uncertain. In order to investigate 
if decreased band intensities in activated platelet lysates was due to technical difficulties with 
lysate preparation, western blots of integrin am, were routinely analysed in parallel (Figure 
3.5A and 3.5B). Bands intensity for both PINCH-1 and am, were measured using ImageJ 
method programme. In all cases, the band intensities for am> was identical across all lysates 
(Figure 3.5B). This confirms that the decrease in PINCH-1 band intensity observed in 
activated platelets is not due to difficulties in solubilizing lysates from activated platelets but 
rather is due to modification or degradation of PINCH-1 protein.
To conclude, PINCH-1 protein is expressed in human platelets. PINCH-1 (D-18) antibody is 
an apropriate antibody for use in these studies and gives reproducible results. Adjusting the 
protein loading concentration is important for better band detection. Finally, the observed 
intensity of platelet PINCH-1 protein is altered with the activation states of the platelets. 
Thus, PINCH-1 appears to be degraded in response to cellular activation. This strongly 
suggests that this protein plays an active role in platelet activation. The fact that the integrin- 
derived peptide Pal-KVGFFKR also affects PINCH-1 protein intensity is strongly suggestive 
for a potential role for this protein in integrin activation. Moreover, integrin must somehow 
stabilize the activation dependent proteolytic degradation of PINCH-1. Again, this is 
supportive of a role for PINCH-1, either directly or indirectly, in the control of integrin 
activation.
3.2.3 Hic-5- Identification of Hic-5 (TGFB1I1) in three different platelets’ statuses.
Western blot experiments were done to detect the presence of the protein Hic-5 in human 
platelets. Two different clones were used, (F6 : sc-137051) (Hic-5, SCBT-b) and (H75: sc- 
28748) (Hic-5, SCBT-a).
The first Hic-5 antibody (F6) was not an ideal choice for Hic-5 protein detection. The initial 
experiments displayed faint bands. After four unsuccessful attempts (Figure 3.4A) with no 
consistent results, we concluded that the Hic-5(F6) antibody is not selective, reproducible or 
specific and was not used in any further experiments.
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Therefore, the second antibody Hic-5(H75) was used. Hic-5(H75) antibody was used in a 
previous study in platelets (Rathore et al., 2007). Western blot experiments were successful in 
detecting Hic-5 protein bands. Hic-5 protein is present in human platelets and the reactive 
bands are persistently found as a doublet band with molecular weight of 45kDa and 55kDa 
(Figure 3.4B). This observation is consistant with previous studies (Osada et al., 2001) and 
others, where it was hypothesised that Hic-5 protein consists of more than one isoforms.
It was observed too that Hic-5 bands differ in intensity depending on the activation status of 
the platelet. The 55kDa band of the resting platelet sample for Hic-5 protein was observed to 
be weaker than the activated bands at 55kDa (TRAP and Pal-FF samples). Furthermore, the 
activated samples (TRAP-activated and Pal-FF) have equal intensities. On the other hand, the 
intensity of the 45kDa bands is highest in resting platelets and decreases in intensity following 
activation with TRAP and Pal-FF (Figure 3.4C).
In summary, Hic-5 protein exists as two isoforms in resting and activated platelets. The 
relative intensity of the Hic-5 protein bands is altered in activated platelets. Also, Hic-5(H75) 
antibody is selective, reproducible and specific.
3.2.4 am, (SZ.22) - The model protein
SZ.22: sc-59923 antibody was used to probe for the anb-chain of the integrin 04^3  in human 
platelets (allb, SCBT). Anti-anb detects the protein at 136kDa. We could not locate previous 
publications about sc-59923 (SZ.22) antibody in particular, but there were other antibodies 
that corresponds to the integrin am, from different companies.
One of the project’s aims is to detect the co-localisation of the proteins PKA Rla, PINCH-1 
and Hic-5 in resting and activated platelets with the integrin a m ^ . The integrin aubfc exists 
abundantly in platelet cells. It is present on the plasma membrane of circulating platelets in an 
inactive or quiescent state. The anb chain of it has the distinctive aminoacid sequences 
KVGFFKR. Therefore, we used it as a control antibody to compare our results with.
SZ.22 antibody was used in western blot experiments. The integrin anb chain was detected in 
human platelets. SZ.22 antibody is selective and reproducible and is reliable in experiments. It 
possesses precise standard results. The bands are consistently between 120kDa and 140kDa, 
clear, thick, and always appear as a strong signal on a bright background (Figure 3.5).
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The experimental conditions used for SZ.22 antibody are the same for every adjacent 
antibody that was used in parallel, such as time for primary and secondary antibody 
incubation, blocking conditions and gel percentage.
To conclude, the steps that were used during western blots experiments were to identify if  the 
antibody is in any previous publications and if not, to examine using the data sheet with trial- 
by-error approach. Next, we wanted to establish the appropriate gel percentage to improve the 
working techniques. In addition, the proteins PK A Rla, PINCH-1 and Hic-5 were detected in 
resting and activated platelets. SZ.22 is an ideal antibody that can be used in platelet studies 
as a positive loading control.
30
WB: PKARla  
(3546C2a) Primary
Antibody
Dilutions
(1:1000)
50KD»
WB: PKA Rla  
(C-14)
2.5(ig Protein 
Loading Concentration
(1:200)
(1:200)
(1:200) 48kDa_.
Figure 3.1. PKARla protein is expressed in human platelets at 48kDa as doublets.
Washed platelets were left untreated or were treated with either TRAP (lOjoM) or Pal-FF 
peptide (lOOpM) and allowed to aggregate for 3 minutes at 37°C. The samples were lysed and 
resolved in SDS-PAGE under reduced conditions and probed for PKARla as follows: (A) 
1:1000 dilution of PKARla (3546C2a) antibody or (B) 1:200 dilution of PKARla (3546C2a) 
antibody to detect PKARla protein. In panel (C) in non-reduced platelet lysate a band is 
observed at 160kDa using PK A Rla (C-14) antibody at (1:1000) dilution. The same samples 
are analyzed under reducing conditions in panel (D) using a 1:200 dilution of PKARla (C-14) 
antibody. In all samples 2.5ug of protein was loaded per lane. The western blot shown is 
representative of one of five independent experiments.
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Figure 3.2. The difference in bands intensity (48 and 55 kDa) for PKARla following 
platelet activation. Band’s intensity of PKARla protein identified by the C-14 antibody at 
48 kDa (blue bars) and 55 kDa (red bars) was measured in inactive platelets (resting) and 
active platelets (TRAP and Pal-FF). Data are represented as mean ± SEM for 5 independent 
experiments.
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Figure 3.3. PINCH-1 protein is expressed in human platelets at 35kDa.
Washed platelets were left untreated (resting) or were treated with either TRAP (IOjjM) or 
Pal-FF peptide (100|aM) and allowed to aggregate for 3 minutes at 37°C. The samples were 
lysed and resolved in SDS-PAGE under reduced conditions. (A) PINCH-1 protein was 
detected using western blot analysis. (B) am, protein was detected in parallel for every protein. 
In all samples 2.5ug of protein was loaded per lane. The western blot shown is representative 
of one of three independent experiments. (C) The difference in bands intensity of PINCH-1 
protein following platelet activation. The intensity of PINCH-1 protein bands was measured 
in inactive platelets (resting) and active platelets (TRAP and Pal-FF). Data are represented as 
mean ± SEM for 6 independent experiments. * indicates a significant difference of P<0.05 
compared to resting platelets, as determined by two-tailed student T-test
33
W B : H ic -5  (F 6 ) v<
* V  &  4 '
W B : H ic-5  (H 75)
(1:200) Prim ary  
Antibody Dilutiun
K D a S O -
W B : SZ.22
(1:1000) P rim a ry  
A n  tibodv D ilution
K D a I3 7 -
lOfig Lo a d in g  
Protein Concentration
(D) Hic-5 Protein (n=4)
________ ________  «SSkDaBand
5^ «i45kDaBand
Resting TRAP pal FF
Figure 3.4. Hic-5 protein is expressed in human platelets at 55kDa.
Washed platelets were left untreated (resting) or were treated with either TRAP (10pM) or Pal-FF 
peptide (100(jM) and allowed to aggregate for 3 minutes at 37°C, The samples were lysed and 
resolved in SDS-PAGE under reduced conditions. Hic-3 protein was detected in western blot analysis 
using (A) Hic-5(F6) antibody at (1:200) dilution and (B) Hic-5(H75) antibody at (1:200) dilution. (C) 
aUb protein was detected in parallel for every protein. (B-C) In all samples lOug o f protein was loaded 
per lane. The western blot shown is representative o f 4 independent experiments. (D) Bands’ intensity 
o f Hic-5 protein after platelet activation using Hic-5(H75) antibody. Band’s intensity of Hic-5 protein 
at 45kDa (blue bars) and 55kDa (red bars) was measured using Image J software in inactive platelets 
(resting) and active platelets (TRAP and Pal-FF). Data are represented as mean ± SEM for 4 
independent experiments. * indicates a significant difference of P<0.05 compared to resting platelets, 
as determined by two-tailed student T-test
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Figure 3.5. Hum an Platelets express the integrin «ubPi at 137kDa.
(A.) Washed platelets were left untreated (resting) or were treated with either TRAP (IOjxM) or Pal-FF 
peptide (100uM) and allowed to aggregate for 3 minutes at 37°C. The samples were lysed and 
resolved in SDS-PAGE under reduced conditions. The allb protein was detected using SZ.22 (am,) 
antibody in western blot analysis. In all samples 2.5ug of protein was loaded per lane. The western 
blot shown is representative of 4 independent experiments. (B) Bands’ intensity of a]Ib protein after 
platelet activation. Band’s intensity of a® protein was measured in inactive platelets (resting) and 
active platelets (TRAP and Pal-FF). Data are represented as mean ± SEM for 5 independent 
experiments.
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Table 3.1. List of 44 proteins that were identified by LC-MS/MS. The table shows the mean 
intensities (and total peptide counts per protein, shown in parentheses) for proteins that were found in 
resting and activated platelet samples and in platelet lysates. Highlighted in bold text (and coded in the 
leftmost column) are proteins that have been previously identified in the literature (P) or which were 
identified in protein chip experiments (c). Proteins coded as (a) were identified in peptide affinity 
chromatography experiments (Raab et al., 2010).
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3.3 Discussion
In this chapter we have identified antibodies adequate for detecting the proteins PKAR1 a, 
PINCH-1 and Hic-5 in human platelets. Western blot analysis was used to demonstrate the 
presence of these proteins in lysates from inactivated (resting) human platelets, TRAP- 
activated and Pal-FF activated platelets. The most abundant platelet-protein, integrin allb, 
was analysed in parallel with the three novel proteins. Furthermore, proteins’ changes were 
recognized upon cellular activation and studied using densitometery analysing softwares. 
Treatment with a strong platelet agonist such as TRAP (lOfiM) or a weak agonist such as Pal- 
FF peptide (100(iM) for three minutes alter protein expression and distribution.
3.3.1 PK A R la- Identification of P K A R la  in human platelets
The difference in the antibody type can influence to an extent the results produced in western 
blot analysis. That was illustrated in two PK A R la antibodies that have been used. The first 
(3546C2a) is monoclonal (Figures 3.1A and 3 .IB) and the second (C-14) is polyclonal 
antibody (Figures 3.1C and 3.ID). Polyclonal antibodies often have the advantage of better 
antigen recognition as they represent a group of epitopes that are available to bind antigens. 
Thus, polyoclonal antibodies result in a higher chance of immunogen detection as they 
recognize multiple epitopes on a single protein (Bordeaux et al., 2010). In contrast, 
monoclonal antibodies will only recognize a single epitope. Morover, if the single epitope 
recognized by the monoclonal antibody is complex, it may be denatured by the SDS-PAGE 
preparation procedure. However, commercial suppliers usually declare in their data sheets if 
antibodies are suitable for western blots.
It was detected that the isozymes (a  and P) of regulatory subunit I of protein Kinase A exists 
in human neoplastic B cell line (Reh) (Tasken et al., 1993). Moreover the regulatory subunit 
la  is distributed almost throughout the whole body (Bossis and Stratakis, 2004). In a previous 
study by our group using peptide-affinity chromatography and LC-MS/MS analysis, it was 
identified that PK A R la was present in human platelets, demonstrated in Table 3.1 (Raab et 
al., 2010). Although this study showed it to be present in low abundance, it was considered to 
be interesting as its binding to the mtegrin-derived peptide differed according to the activation 
state of the platelet lysate. By doing Western blot analysis this study further proves that 
PK A Rla protein exists in human platelets.
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In the experiments, there were two samples subjected to reduced and non reduced conditions, 
with and without DTT respectively. Results in our experiments showed that in samples 
without the reducing agent DTT the PKA complex remains intact and bands were identified at 
the high molecular weight of 160kDa (The Universal Protein Resource) consistant with its 
known tetrameric structure, as seen in Figure 3.1C. In contrast, PKAR1 was identified at the 
expected molecular weight range of 48kDa when samples were reduced with DTT to 
monomers. This confirms that the proteins identified in my studies is indeed the PKARla 
monomer at 48kDa in it’s reduced condition and the PKA complex at 160kDa in it’s non­
reduced form. Therefore, PKARla is a thiol-dependent complex and is recognized in platelet 
lysates by the (C-14) antibody.
The bands of PK A R la appear as a doublet at 48kDa and 55kDa. This was consistently 
observed in western blot analysis (n=5) as seen in Figure 3 .ID. The reason behind the doublet 
remains unknown. The existence of genetically distinct isoforms is not documented. 
Therefore, proteins of separate discreet molecular weights could result from enzymatic 
modification such as phosphorylation, post translational modification or protease action 
(enzyme cleavage). For example, the higher band at 55kDa could be a product of 
ubiquitination, as the difference in molecular weight between the doublets is 7-8 kDa, and 
ubiquitination results in the addition of an 8kDa ubiquitin moiety to a protein. Also, PKAR1 a  
has been associated with the ubiquitin pathway by other groups (Lignitto et al., 2011).
The intensity of the lower bands at 48kDa was always the same for the three samples. It was 
intense in all blots, but the upper bands at 55kDa were not as intense as the lower bands in all 
cases. The band intensity from the TRAP-activated sample was the strongest for both bands 
(Figure 3.ID).
The 48kDa band that is the main expected molecular weight of the protein PKARla is intense 
in all blots. The intensity of the 48 kDa changes from resting to activated platelets. In 
contrast, the 55 kDa was not intense as the lower band (48kDA). The intensity of 48kDa is 
greatest in the TRAP-activated sample followed by the resting then the Pal-FF activated 
samples. On the other hand, the Pal-FF activated sample is greater than the resting sample in 
intensity for the55 kDa band (Figure 3.2). The intensity’s results were determined using UVP 
imaging system (Vision WORKsLS).
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To summarize, PKARla protein is expressed in human platelets, as a doublet at 48kDa and 
55kDa. The expression pattern is altered upon cellular activation. PKARla (C-14) antibody is 
adequate for western blot analysis.
3.3.2 PINCH-1- Identification of PINCH-1 (LIMS1) in human platelets
Western blot analysis was done to probe PINCH-1 protein from human platelet lysates (n>6 ). 
Experiments showed that PINCH-1 protein is present in human platelets. These results were 
consistent with the data obtained in the Mass spec experiments published by our platelet 
function group (Raab et al., 2010). PINCH-1 protein appeared as single band at approximately 
37kDa.
We found in the study that the intensity of the bands’ was different from resting to activated 
platelet lysate samples; the band intensity was the highest in resting platelets followed by the 
activated samples (Pal-FF then TRAP).
The decrease in band intensity is most likely associated with protein degradation. Results 
showed that the bands degrade upon platelet activation. TRAP is referred to as a strong 
activator of platelets and PAL-FF is regarded as a weak activator of platelets. Consistent with 
this, the degree of degradation of PINCH-1 protein is higher with TRAP than with PAL-FF 
(Figure 3.3.C) suggesting that the association of PINCH-1 with the integrin via the KVGFFKR 
region may play a role in PICNH degradation.
Western blot results of PINCH-1 showed that the bands degraded after platelet activation. To 
exclude that the protein possibly degraded due to experimental artefacts such as inadequate 
protein solubilization; all the three samples were treated under the same conditions (reduced 
and vortexed to ensure adequate protein solubolising). A control western blot was analysed in 
parallel with the anti-aiiB antibody (SZ.22). This was to demonstrate almost equal levels of 
protein ans was present in the lysates (Figure 3.3B and 3.5B). Moreover, previous western 
blot experiments of PKARla and Hic-5 showed more intense bands upon platelet activation. 
Suggesting more likely that the changes in PINCH-1 band intensity following platelet 
activation is caused by protein degradation.
In summary, the observed intensity of platelet protein PINCH-1 is altered with the activation 
status of the platelet. This strongly suggests that this protein plays an active role in platelet
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activation. The fact that the integrin-derived peptide; Pal-KVGFFKR also affects PINCH-1 
protein intensity is suggestive for a potential role of this protein in integrin activation also.
3.3.3 Hic-5- Identification of Hic-5 (TGFB1I1) in three different platelets’ statuses.
Hic-5 protein is present in the resting and activated states of the human platelets. Western blot 
analysis of n=4 of human platelet lysates using anti-Hic-5 polyclonal antibody showed the 
presence of two bands (or doublet) at approximately 45 and 55KDa. Both bands are well- 
defined band and not vague. This supports other studies that mentioned that Hic-5 may exist 
as multiple isomers (Hagmann et al., 1998); (Osada et al., 2001). Activation of platelets with 
TRAP and Pal-FF peptide causes a shift in the relative intensities of the two Hic-5 reactive 
bands (Figure 3.4B). The intensity of the lower band (45kDa) decreases with activation 
whereas activation causes the opposite for the the intensity of the upper band (55kDa); it 
increases. This is consistant with a substandial activation-induced post-translational 
modification resulting in a shift in molecular weight. As for PKARla protein, the magnitude 
of the shift in molecular weigh is consistant with a potential ubiquitination reaction. However, 
we did not specifically investigate the possibility of ubiquitination, so can only speculate that 
this is the cause of the altered molecular weight.
Hic-5 is a cytoskeletal protein that moves from cytosol and membrane skeleton in resting 
platelets into the cytoskeleton upon anbP3 activation (Osada et al., 2001). Researchers like 
Rathore and colleagues found that Hic-5 protein is phosphorylated following platelet 
activation and spreading on fibrinogen. However, the Hic-5 doublet in our studies are not 
entirely consistant with phosphorylation. Firstly, the molecular weight difference is too high 
(more than 5 kDa) as seen in Figure 3.4B, secondly, the doublet exist in both resting (SI) and 
activated (S2 and S3) platelet samples. Nevertheless, the higher molecular weight component 
(55kDa) has a greater intensity following platelet activation with either TRAP or Pal-FF 
peptide, where both have equal intensities, suggesting that some kind of post-translational 
modification is occurring following platelet activation. In summary, the intensity of the 
45kDa band is highest in the resting platelet sample followed by the TRAP and then the Pal- 
FF samples. This is consistent with the result that the 55kDa band achieves greater intensity 
upon platelet activation, showing that the protein alters with the activation status of the 
platelet.
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In conclusion, Hic-5 protein presents in human platelets as doublets (45 and 55 kDa). The two 
forms appear to be interconvertable during cellular activation. This strongly suggests that this 
protein plays an active role in platelet activation. In addition, Hic-5 (H75) antibody is a good 
choice for western blot experiments.
3.3.4 The control antibody SZ.22 (aDb subunit)
SZ.22 monoclonal antibody was used to probe the am, subunit of the integrin am,P3. This 
integrin presents abundently in human platelets. Western blot analysis of am, protein show 
consistent results of strong bands suggesting that the platelets are rich of it (Figure 3.5A). 
Further more, it was observed that there are similar levels of anb protein in all diffemt platelet 
statuses; resting, TRAP-activated and Pal-FF activated showing constancy and uniformity 
(Figure 3.5B). We concluded that the protein am, is a reliable protein to be used as a good 
reference-standard in western blot analysis that is conducted on human platelet lysate 
samples, to allow determining the samples loaded onto gels.
In conclusion, the proteins PKARla, PINCH-1 and Hic-5 are present in resting and activated 
platelets. PKARla and Hic-5 proteins appear as doublets. The relative intensity of the protein 
bands alters with platelet activation, supporting a hypothesis that these proteins play a role in 
platelet activation with TRAP and with the integrin-derived peptide KVGFFKR. The higher 
molecular weight of the doublet possibly represents a post-translationally modified varient 
possibly due to enzymatic activity such as phosphorylation or ubiquitination. In addition, 
PINCH-1 protein, which is apparent as a monomer of the expected molecular weight (37kDa), 
is also modified by cellular activation. However, in the case of PINCH-1, the protein is 
apparently degraded during platelet activation Finally, SZ.22 is an antibody that recognizes 
the abundant platelet protein am, and can be used successfully in platelet studies as a positive 
loading control. The intensity of SZ.22 staining in western blots remains constant across all 
samples demonstrating that our protocol for solubilising platelet proteins is effective in 
yielding equivalent amounts of protein from resting and activated platelets. Moreover, this 
result allows us to conclude that the specific activation dependent changes we observed in 
PKARla, Hic-5 and PINCH-1 are not artefactual but represent real changes in protein 
abundance, protein modification or protein degradation that occurs in response to platelet 
activation with TRAP or the integrin-derived peptide KVGFFKR. Thus we have 
demonstrated that relative to anb protein levels in platelets, PKARla levels appear to increase
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following platelet activation whereas PINCH-1 levels appear to decrease. It is likely that the 
changes in PINCH-1 band intensity following platelet activation is caused by protein 
degradation. It is more difficult to explain the apparent increase in intensity of PKARIa. It is 
possible that the antibody chosen recognizes an epitope that is better exposed following some 
activation-induced post translational modification.
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4.1 Introduction
In a proteomic study done by the platelet function group here in RCSI, it was found that there 
are numerous possible platelet integrin a,nb[33 binding proteins with unidentified roles within 
the platelet cytoplasm (Raab et al., 2010). Three proteins in particular, identified by their 
affinity interaction with the integrin regulatory motif, KVGFFKR by LC-MS/MS were 
PKARla, PINCH-1 and Hic-5. These cytoplasmic proteins were identified as interesting 
proteins and were worth pursuing as potential integrin regulatory proteins. These proteins 
interact with the conserved motif KVGFFKR of the integrin anb subunit according to our mass 
spectrometry data but may do so as primary, secondary or tertiary interactors of the integrin 
arib subunit.
A group in the United States had previously published that Hic-5 protein does not bind to the 
integrin allbp3 (Liu et al., 1999). In their study, they focused on paxillin binding to other 
alpha integrins but examined Hic-5 binding to the platelet integrin as a small part of their 
study. However, we were confident that for Hic-5, our mass spec data was strongly suggestive 
of an interaction of this protein with the integrin cytoplasmic tail. We therefore set out to test 
the hypothesis that PKARla, PINCH-1 and Hic-5 may bind to the integrin am» subunit by 
using co-immunoprecipitation as a technique. Very simply, the idea behind this application is 
to remove one protein (protein X) from a cell and subsequently try to detect if another protein 
(protein Y) is attached to this, suggesting a biological interaction.
To examine this hypothesis we did the following co-immunoprecipitation experiments:
(1) The platelet integrin anbPi was immunoprecipitated (IP) from washed platelet lysates with 
the mouse antibody (SZ.22) which is raised against the integrin anb-chain. Following this IP, 
we probed for the three proteins of interest thought to be integrin interactors: (A) PKARla
(B) PINCH-1 and (C) Hic-5 by western blot analysis. The antibodies used in this part of the 
study have been characterized in Chapter 3 of this thesis. Western blot analysis of integrin am, 
in the immunoprecipitated samples served as a positive control. In parallel, platelet lysates 
were subjected to immuoprecipitation by a control IgG antibody. This served as a negative 
control. Finally, samples of whole platelet lysates were separated on the SDS gels and 
analysed in each western blotting experiment. The identification of a protein band in these 
lysate samples was essential to confirm the the exact position of the protein-of-interest in the
western blot, and to act as an additional positive control.
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(2) In a separate series of experiments, Hic-5 protein was immunoprecipitated from platelet 
lysates by using a rabbit anti-Hic-5 antibody. We immunoprecipitated (IP) with Hic-5 to study 
the hypothesis from both angles. Then we western blotted for (A) Hic-5 (B) Integrin am, with 
SZ.22 and (C) Gplba antibodies. We probed for Hic-5 protein to ensure there was a 
successful pull down but also with anti-integrin antibody (SZ.22) to try and determine if this 
protein co-associated with Hic-5. Since it was found in an earlier study that Hic-5 protein 
interacts with a different platelet adhesion molecule, GPIba (Arthur et al., 2011), we also 
probed for this protein in the Hic-5 immunoprécipitation samples. This provided us with an 
extra positive control for our experiment, helping us to verify the effectiveness of our 
protocol. However, due to the lack of time, we could not study the interaction between the 
proteins PKARla, PINCH-1 and Hic-5 or immunoprecipitate with PKARla and PINCH-1 
antibodies.
The role of the proteins PKARla, PINCH-1 and Hic-5 in human platelets is unidentified. 
Therefore, in this chapter we aimed only to study the interaction between the integrin amr 
subunit and the proteins PKARla, PINCH-1 and Hic-5. In more detail, I will now describe 
the experimental conditions in preparing the platelets for a co-IP experiment.
Methods
There were nine samples in each experiment. For each experiment, three separate platelet 
preparations are collected and solubilised in lysis buffer. These samples are the same as those 
described in Chapter 3 and comprise resting platelets (R), platelets that have been activated 
with TRAP (T; 10(iM for 3 minutes at 37°C) and platelets that have been activated with Pal- 
KVGFFKR Peptide (P; lOO^ iM for 3 minutes 37°C). Each of these samples is processed as 
follows: (1) A small sample is taken from each lysate. Part of this is subjected to a Bio-Rad 
protein estimation assay and the remainder is stored in SDS Sample buffer until needed. (2) 
Of the remaining sample, 50% is subjected to immunoprécipitation with a non specific 
antibody (i.e. normal IgG) from the same species as the pull-down samples. (3) The 
remainder of the sample is subjected to immunoprécipitation with a specific antibody (SZ.22 
or Hic-5). The protocols that were used depend on the type of the immunoprecipitating 
antibodies and whether it is a monoclonal or a polyclonal antibody. Protein G-Sepharose 
beads were used with monoclonal antibody such as SZ.22 and Protein A-Agarose beads were
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used with polyclonal antibody. The following is a brief description of the Co-IP protocol as 
mentioned previously in Chapter 2 (Materials and Methods):
Protein A-Agarose beads were used to immunoprecipitate with polyclonal antibody and 
protein G-Sepharose for immunoprécipitation with the monoclonal antibody. 25 Dl for every 
reaction of beads was washed 3 times from slurry with ice-cold PBS and incubated rotating 
for 1 hour at 4°C with 0.5ml platelet (protein concentration ~600xl 03/(xl) lysates for 
preclearing. The mixture was microfuged briefly to pellet the beads (72g for 30 seconds). The 
supernatant was divided into two and removed to fresh eppendorfs. The first eppendorf is the 
negative control which is incubated with an IgG-antibody and the second is for the pull-down 
which is incubated with the immunoprécipitation antibody. Both antibodies added for 
incubation of equal amounts (5|ig/500|il) for Hic-5 and Rabbit IgG and (0.2-2|xg/500jxl) for 
SZ.22 and mouse IgG and kept rotating at 4°C from 2 hours to overnight. Then, equal 
amounts (25(0.1) of fresh washed beads were added to both eppendorfs and kept rotating for 1- 
2 hours at 4°C. After that, the beads were pelleted gently and washed 3 times with PBS, eluted 
with 2X sample buffer, boiled at 95 °C for 3minutes and spun. Samples were ready for use.
The band’s intensity was determined using ImageJ software for all western blots in this 
chapter. The bands intensity was normalized to all samples’ bands in the experiment. Thus the 
total intensity of the western blot bands was summed for the 9 lanes on each gel. This was 
assigned a value of 100. Each band was expressed as a percentage of this total. In this way, 
the variance between experiments was minimized.
We determined that the experiments were successful for the following reasons. First the 
platelet lysate samples should contain the protein of interest at the correct molecular weight. 
Secondly the negative control samples (IgG pull-down) should not show any bands 
corresponding to the proteins of interest, or the intensity of the bands should be so much less 
than the intensity of the bands observed in the presence of the specific antibody. Thirdly, the 
specific antibody should precipitate the proteins of interest. In particular, it should be able to 
precipitate itself. Thus when SZ.22 was used as the immunoprecipitating antibody, samples 
were also western-blotted with SZ.22 to ensure specific and substantial pull-down of this 
protein. Band intensity was determined using ImageJ software for all western blots in this 
chapter.
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4.2 Results
We examined the binding of PKARla, PINCH-1 and Hic-5 proteins to anb-subunit, by 
selectively immunoprecipitating the am, protein. Immunoprecipitating with am, protein let us 
assess whether the proteins PKARla, PINCH-1 and Hic-5 bind directly or not to the integrin. 
We successfully immunoprecipitated the am, protein when using anti-mouse SZ.22 antibody 
and when we immunoprecipitated with a non-specific normal mouse IgG antibody the results 
were negative (as expected), demonstrating that the SZ.22 antibody is capable of specifically 
immunoprecipitating the integrin am, from platelet lysates. As can be seen in Figure 4.1 A, the 
immunoreactive band for SZ.22 runs at an identical molecular weight in total platelet lysates 
as in the SZ.22 pull-down experiments.
4.2.1.1 Western blot with SZ.22 antibody
In every experiment we regularly blotted with the antibody SZ.22 that probes the anb-subunit 
of the integrin. SZ.22 blot is a control in the experiments. We assessed that the experiment 
was successful by checking there were no bands for the negative control samples and that the 
integrin subunit anb in the lysates bound to the antibody SZ.22 in the pull down samples. We 
consistently got strong bands in the pull-down samples and no bands in the negative control 
samples n=5 (Figure 4.1 A). The densitometry analysis data for amrsubunit showed that there 
is a significant difference between the pull down samples and the negative control samples 
(Figure 4.2A). This strongly suggests that the experiments are successful. Following this 
success, we then wanted to determine if the integrin managed to pull-down a complex of co­
associating platelet proteins by using the following antibodies: PKARla, PINCH-1 and Hic-5.
4.2.1.2 Western blot with PK A Rla antibody
Western blots of the co-IP experiment were done to detect whether PKARla binds to the 
integrin amrsubunit or not. Four out of six experiments were successful. Two were deemed 
unsuccessful because at times it would seem a lot of protein was pulled down non-specifically 
and the protein of interest could not be identified in the lysate samples or there was protein 
degradation.
The remaining results show that there is more PKARla protein pulled down with the IgG 
antibody in the negative control samples than the pull down samples using SZ.22 antibody,
4.2.1. IP with SZ.22 antibody (aUb-chain of the integrin);
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showing that PKARla protein does not bind specifically to the integrin in resting, TRAP or 
Pal-FF activated samples as demonstrated in Figure 4. IB.
Densitometry analysis summarizes the results obtained in 4 separate experiments and 
illustrate that there is a lot of non-specific binding in all negative control samples (Figure 
4.2B). Indeed, this protein was identified originally in a mass spec analysis of proteins 
binding to a KVGFFKR-peptide column. Its ability to bind non-specifically to an irrelevant 
antibody may be related to its ability to bind to the affinity column.
4.2.1.3 Western blot with PINCH-1 antibody
Immunoprecipitated samples were next immunoblotted with an antibody that recognizes 
PINCH-1 protein. Figure 4.1C shows a western blot of PINCH-1 antibody. There are almost 
equal amounts of protein both in the negative control samples and the pull-down samples, 
suggesting that, like PKAR1, there is no specific binding of PINCH-1 to the integrin a ir  
chain. Densitometry analysis also showed that the band-intensity for the resting and activated 
samples is higher in the negative control samples than in the SZ.22 pull-downs (Figure 4.2C).
4.2.1.4 Western blot with Hic-5 antibody
Although the Hic-5 protein is identified in our proteomics experiments as binding to the 
integrin (am, -subunit) regulatory peptide (Raab et al., 2010), an old study by (Liu et al., 
1999) appeared to show the opposite results and states that Hic-5 does not bind to the am, 
integrin. However, Hic-5 binding showed the strongest signal in our proteomics experiments, 
so we were keen to establish if it was able to bind to the platelet specific integrin. Therefore, 
we immunoprecipitated with SZ.22 antibody and probed for Hic-5 protein. Co-IP experiments 
(n=5) showed that the Hic-5 protein binds significantly to the am, beads in the resting and Pal- 
FF-activated samples (Figure 4. ID).
In one particular experiment, there was a significant difference between the pull-down and 
negative control samples (Figure 4.3A). In this experiment, the resting platelet lysate sample 
was observed as two distinct bands at 45kDa and 55kDa representing Hic-5 protein. The 
bands were strong on a bright background. The corresponding band in the negative control 
samples was vague and faint and more consistent with the profile of the heavy chain of the 
antibody. There were just 2 positive control samples in this experiment; the resting and 
TRAP-activated platelet lysates, showing bands at approximately 55kDa. This experiment
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was included in the densitometry analysis (Figure 4.2D) with the rest of the experiments. 
There is no representative image for the control gel SZ.22 as the gel was not well polymerized 
and the samples did not run smoothly (Figure 4.3B).
We conclude from these experiments (Figures 4 .ID and 4.2D), that there appears to be a co­
association between integrin anb and Flic-5 in resting and Pal-FF activated platelets. The 
evidence for co-immunoprecipitation of Hic-5 with am, in the TRAP-treated samples is not 
strong.
To summarize, there is no direct interaction between the integrin am,b3 and the proteins 
PKARla and PINCH-1. In contrast, the results of the SZ.22 pull-down experiments suggest 
that there is an interaction between the integrin aiibb3 and Hic-5 protein in resting and Pal-FF 
activated platelets but not in TRAP-activated platelets.
4.2.2 IP with Hic-5 antibody
In order to confirm the apparent co-association of Hic-5 with integrin otiib in resting and Pal- 
FF activated platelets, we repeated the co-IP experiments but changed the precipitating 
antibody to the anti-Hic-5 antibody (H-75: sc-28748) and western blotted against the integrin 
am,. It was proven in a previous study that Hic-5 protein binds to the integrin Gplba (Arthur 
et al., 2011). Therefore, we used this fact in our experiments to provide us with an additional 
positive controls. The negative control samples were immunoprecipitated with a non specific 
normal rabbit IgG antibody in a similar manner to the use of mouse IgG controls for the 
SZ.22 immunoprécipitation experiments.
4.2.2.1 Western Blot with Hic-5 antibody
We probed every Hic-5 immunoprécipitation experiment with a mouse anti-Hic-5 antibody. It 
is the main control in the experiment. In these experiments we show the Hic-5 protein is 
immunoprecipitated with the anti Hic-5 antibody and showed, as expected, a distinct band at 
55kDa corresponding to bands observed in the platelet lysate samples (Figure 4.4A). This 
band does not correspond to the heavy chain of the antibody because the primary antibody 
was from a different host species (mouse). It is noteworthy that the 55kDa band is absent or 
greatly reduced in samples immunoprecipitated with the negative control antibody. This 
demonstrates that the Hic-5 antibody is highly specific in immunoprecipitating Hic-5 protein 
from platelet lysates. The intensity analysis for Hic-5 protein co-immunoprecipitation showed
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successful experiments, as the intensity of the pull-down bands are higher in all samples than 
the negative controls (Figure 4.5A).
4.2.2.2 Western Blot with Gplba antibody
We next western blotted with a Gplba antibody to confirm the interaction of GpIb/IX/V 
complex with Flic-5 protein that was first reported by (Arthur et al., 2011). This was an 
additional positive control in the experiment. The results showed that we successfuly 
precipitated Gplba (Figure 4.4B). The band’s intensity confirmed that Gplba was bound to 
Flic-5 proteins in both resting and TRAP-activated platelets, as there is a difference between 
the pull-down and negative control samples (Figure 4.5B). However, it is highly noteworthy 
that the integrin-derived peptide Pal-KVGFFKR inhibits this interaction.
4.2.2.3 Western Blot with SZ.22 antibody (integrin anb-chain)
Finally, we probed the Hic-5 immunoprecipitates for the a®  protein by western blotting with 
the SZ.22 antibody. The results shown in Figures 4.4C and 4.5C demonstrate that there is 
evidence for weak binding of an, to Hic-5. In three out of four experiments, there appears to 
be evidence of some co-association of am, with Hic-5 above a background level, but the 4th 
experiment causes this overall result to be diminished (Figure 4.5D).
We conclude therefore that our experiments show evidence for co-association of am, with 
Hic-5 in platelet lysates. This result is not the same as we obtained from co- 
immunoprecipitation with SZ.22 antibody (am,-subunit) and probing for Hic-5 (Figure 4.2D) 
where we saw evidence for co-association of these proteins only in the resting and Pal-FF 
activated platelets. Further experiments will need to be performed to confirm this difference.
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Figure 4.1. Co-immunoprecipitation of SZ.22 antibody with ctnb, PKARla, PINCH-1 
and Hic-5 proteins. Washed platelets were left untreated (resting) or were treated with either 
TRAP (K)|iM) or Pal-FF peptide (100|xM) and allowed to aggregate for 3 minutes at 37°C. 
The samples were lysed and immunoprecipitated with SZ.22 antibody (otnb chain of the 
integrin). Western blot analysis was done using (A) anti-SZ.22 antibody, (B) anti-PKARla 
antibody, (C) anti-PINCH-1 antibody and (D) anti-Hic-5 antibody. Protein loading 
concentration is approximately 2.5(ig per lane. The western blot is representative of one of 4 
or more independent co-immunoprecipitation experiments. Hic-5 western blot was cropped 
and rearranged for presentation purpose only. An original image of the blot is attached at the 
end of the thesis (please see page 64).
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Figure 4.2. Densitometry analysis of proteins’ interaction with am, integrin.
Difference in band intensity between dm, integrin and selective proteins (A) anb-subunit, (B) PKARla,
(C) PINCH-land (D) Hic-5 and non-specific proteins in lysates. Data are represented as mean ± SEM 
for 3 independent experiments. * Indicates P <0.05 compared to IgG control-IP sample, as assessed by 
two-tailed Student T test. NS= non significant.
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Figure 4.3. Co-immunoprecipitation of SZ.22 antibody with Hic-5 and am, proteins.
Washed platelets were left untreated (resting) or were treated with either TRAP (IOjxM) or 
Pal-FF peptide (lOOpM) and allowed to aggregate for 3 minutes at 37°C. The samples were 
lysed and immunoprecipitated with SZ.22 antibody (ain> chain of the integrin). Western blot 
analysis was done using (A) anti-Hic-5 antibody and with (B) anti-SZ.22 antibody. Protein 
loading concentration is approximately 2.5pg. The western blot is representative of 5 
independent co-immunoprecipitation experiments.
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Figure 4.4. Hic-5 antibody selectively immunoprecipitates Gplba and anb
Washed platelets were left untreated (resting) or were treated with either TRAP (lOfxM) or 
Pal-FF peptide (lOOpM) and allowed to aggregate for 3 minutes at 37°C. The samples were 
lysed and immunoprecipitated with anti-Hic-5 antibody. Western blot analysis was done using
(A) anti-Hic-5 antibody, (B) anti-Gplba antibody and (C) anti-SZ.22 antibody. Protein 
loading concentration is approximately 2.5 jig. The western blot is representative of one of 
four independent co-immunoprecipitation experiments for SZ.22 and 5 for both Hic-5 and 
Gplba. Averaged data is shown in Figure 4.5.
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Figure 4.5. Densitometry analysis of proteins’ interaction with Hic-5 protein.
The difference in band-intensity between Hic-5 interaction with selective proteins (A) Hic-5,
(B) GPIba and (C-D) anb-subunit and non-specific proteins in lysates. Data are represented as 
mean ± SEM for 3 independent experiments. * Indicates P <0.05 compared to IgG control-IP 
sample, as assessed by two-tailed Student T test. NS= non significant.
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4.3 Discussion
In this chapter we have investigated the platelet proteins that bind to the integrin otnbP3 in 
order to verify data obtained from previous mass-spec analysis of proteins binding to an 
integrin-derived affinity column (Raab et al., 2010). These experiments had identified known 
integrin binding proteins (CIB1, Protein phosphatases and RN181) in addition to other 
uncharacterized platelet proteins. Of these, Hic-5 was the protein most enriched on the peptide 
column containing the am, regulatory motif (KVGFFKR). PINCH-1 and PKARla were also 
enriched. All three of these proteins were of interest to the RCSI platelet research group. We 
used the co-immunoprecipitation technique in an attempt to verify and study the interactions 
between these proteins in platelet lysates.
We successfully immunoprecipitated two proteins using separate antibodies. The first protein 
was am, using the antibody SZ.22 and the second protein was Hic-5. Subsequent immunblots 
using antibodies against the proteins am,, PKARla, PINCH-1 and Hic-5 were done to 
determine if these proteins co-immunoprecipitated with the primary immunoprecipitated 
protein, am> or Hic-5. Densitometry analysis was done to examine the results in a quantitative 
fashion.
The validity of our experiments is confirmed by additional experiments and controls; we used 
two different protocols that gave us the same results, and in addition different controls were 
used.
The antibody anti-SZ.22 specifically pulls down the integrin chain am, as expected. Data is 
presented as representative blots (Figure 4.1 A) and by densitometry of 5 independent 
experiments (Figure 4.2A). There was a significant difference between the proteins that were 
pulled down with the IgG and the SZ.22 antibodies confirming that the control antibody is 
selective.
Our co-IP results showed that the proteins PKARla and PINCH-1 do not bind to the integrin 
am directly in human platelet lysates. In contrast, densitometry analysis of Hic-5 protein 
showed that this protein does appear to interact with the integrin am,.
In parallel experiments, the Hic-5 antibody selectively immunoprecipitated Hic-5 protein, as 
assumed. By western blotting Hic-5 immunoprecipitates with the same anti-Hic-5 antibody, 
we observed there was plenty of Hic-5 protein binding to Hic-5 beads and no bands at the IgG
57
beads, showing that Hie-5 antibody is selective for immunoprecipitation experiments. 
Densitometry analysis determined the bands intensity of Hic-5 and showed that the pull down 
bands are significantly higher than the negative control bands in resting and activated platelets 
(Figure 4.5A).
It was found in a previous study (Arthur et al., 2011) that Hic-5 protein binds directly to 
GpIb/IX/V. Therefore we did an extra step that confirms these two points. By successfully co- 
immunoprecipitating Gplba with the anti-Hic-5 antibody, we confirm that our experimental 
immunoprecipitation techniques are correct and that Hic-5 antibody is capable of pulling 
down Hic-5 protein from platelet lysates. The densitometry analysis showed substantial co­
association of Gplb and Hic-5 in resting and TRAP activated platelets but not in Pal-FF 
activated platelets. This raises a question of a role for am>P3 in facilitating the interaction 
between GpIb/IX/V and Hic-5, and is consistent with our earlier result demonstrating a 
potential co-association between integrin am, and Hic-5 in resting platelets. Thus Hic-5 
protein may cross-link GpIb/IX/V and integrin anbP3 in resting platelets. Following activation 
with TRAP, Hic-5 appears to be released from its interaction with am,, as suggested in Figure 
4.2D, but remains associated with Gplba (Figure 4.5B). In contrast, activation of platelets 
with the integrin-derived peptide Pal-FF, destabilizes the integrin anb-Hic-5 interaction in a 
manner that does not permit continued binding of Gplba to Hic-5.
Hic-5 protein had strong binding signal to the platelet integrin am>P3 in our proteomics 
experiments (Raab et al., 2010). As a result, we planned to examine and confirm the integrin 
co-association with Hic-5 protein. We performed co-IP experiments using Hic-5 antibody and 
western-blotted for the integrin. In these experiments, we demonstrate that there is a co­
association of Hic-5 with am>. We observed, in 3 out of 4 experiments resting and activation 
dependent interaction (in TRAP and Pal-FF activated) platelets (Figure 4.5C). Statistical 
significance was only obseverved for proteins from resting platelets in these 3 experiments. 
However, the 4th experiment changes this overall result. If we include this single outlier result, 
the interaction in the resting platelet sample is changed. The mean densitometry images 
shown in (Figure 4.5C) suggest that Hic-5 interacts with integrin am, in platelet lysates from 
resting, TRAP activated and peptide-activated samples.
Nevertheless, there is a high background level of SZ.22 staining observed in the negative 
control lanes in these experiments, making this conclusion somehow dubious. A number of
58
methods were explored in an attempt to reduce this background. Such methods included 
increased numbers and duration of the wash steps performed during the immunoprécipitation, 
changing the salt concentration in the wash buffers, increasing the amount of detergent in the 
wash buffers. However, in all cases, we continued to observe high background staining. Thus 
the results obtained for Hic-5/am, interaction is not clear-cut from these experiments. 
However, the opposite experimental procedure: immunoprécipitation with SZ.22 followed by 
western-blotting for Hic-5, clearly demonstrates a co-association of these proteins in resting 
platelet lysates.
One explanation for the difference in results observed following co-immunoprecipitation of 
am, with Hic-5, and vice versa, is the choice of antibody used. Whereas one antibody was 
used for SZ.22 immunoprecipiation or am, detection, two different antibodies were used in 
experiments with Hic-5 protein. A rabbit polyclonal antibody was used to probe for Hic-5 in 
SZ.22-immunoprecipitates whereas a mouse monoclonal antibody was used to 
immunoprecipitate Hic-5 in experiment. This may be the reason behind the lack of 
complimentarity in the results.
All data is presented as representative images of western blots and the densitometry data was 
illustrated as charts of n number of separate experiments depending on the protein. Statistical 
differences were determined using student T-tests.
Conclusion
We have confirmed that the protocols used in our assays are valid. Using these protocols we 
demonstrated definitively that neither PINCH-1 nor PKARla proteins bind to the integrin am, 
in our co-immunoprecipitation experiments. Finally, we showed that Hic-5 protein interacts to 
the integrin am, but it is possible that this interaction is transient and thus difficult to capture in 
our experiments.
Confocal Imaging
Work performed by another researcher in the laboratory, using confocal microscopy, lends 
support to this conclusion. In a series of imaging experiments on aiibfr-expressing CHO cells 
adhered to immobilized fibrinogen, it has been demonstrated that talin, a cytoplasmic protein
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known to bind to activated integrin, co-localizes with am,(3a at the periphery of a spreading 
platelet (Figure 6.1.1), see below. In this experiment, cells are allowed to adhere to 
immobilized fibrinogen for 45 minutes and are then fixed and stained with two antibodies: 
CD41 stains am>P3 and is labelled as red and an a-talin antibody is labelled green. Co­
localization is visualized as yellow pixels, that are observed when red and green fluors are co­
localized within 10 Angstroms of each other. In Figure 6.1.3, cells are co-stained for integrin 
(red) and RN181, another known integrin binding protein. Like talin, co-localization was 
observed at the periphery of the spreading platelet. Next, cells are co-stained for Hic-5 and 
am,P3 in Figure 6.1.2. In this image, yellow pixels are observed confirming co-localization of 
Hic-5 with anb(33. However, it is notable that this co-localization does not occur at the 
periphery of the spreading platelets, as was observed for talin and RN181. In contrast, 
colocalization is only observed in the region of the adhesome, the point where the cell made 
initial contact with the immobilized fibrinogen. Given that talin and RN181 are known to bind 
to activated inetgrin, and Hic-5 may only bind to the resting conformation of integrin in 
unactivated cells, we then examined the relative staining of cells with RN181 and Hic-5 
(Figure 6.1.4). Strikingly, these two protein appear to label alternate pools of am>P3. We 
suggest that these pools represent activated and resting integrin, respectively.
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Figure 6.1: Co-localization of am>p3 integrin with cytoplasmic proteins.
Platelets or CHO-cells expressing anb[33 were allowed to adhere to fibrinogen-coated glass 
slides for 45 minutes. Cells were then stained as follows: (1) Talin, a know beta-integrin 
binding protein in labeled green (FITC) and anbP3 is stained red (PE). Co-localization is 
observed as yellow pixels resulting from the juxtaposition of red and green pixels. (2) Hic-5 
protein is stained with FITC (Green) and anbP3 is stained red. Note the localization of Hic-5 
in a centralized location but not at the membrane. Co-localization with integrin corresponds to 
the initial adhesome. (3) RN181 protein is labeled with FITC (Green) and anb|33 is stained red 
(PE). Note that RN181 is observed solely at the membrane in these fully spread platelets. (4) 
Hic-5 protein is stained red and RN181 is stained green. Note the opposite localization of 
these two alpha-integrin binding proteins. Hic-5 is only observed in the adhesome and RN181 
is only observed at the periphery of the cytoplasm. (Images courtesy of Seamus Allen, BSc)
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Conclusion: How a scientific knowledge has been advanced by my study?
Western blotting was used to verify the presence of these proteins PKARla, PINCH-1 and 
Hic-5 in human platelets and to examine their capacity to be altered by platelet activation. We 
demonstrated that platelets express all 3 proteins. In addition, I show evidence for activation- 
dependent modification of these proteins in response to pro-thrombotic stimuli. PKARla and 
Hic-5 show evidence of post-translational modification (phosphorylation or ubiquitination) 
whereas PINCH-1 shows degradation in response to platelet activation.
We found in a previous study done using proteomics that known integrin binding proteins 
bind to an affinity column containing the integrin regulatory region, KVGFFKR. This study 
also identified a range of novel potential integrin-regulating proteins. Therefore, we used Co- 
EP technique to confirm the interaction of three of these proteins with the platelet integrin. We 
showed that neither PKARla nor PINCH-1 proteins bind to the integrin chain am,. 
Alternatively, we found that Hic-5 protein probably binds to the integrin. Thus we observe 
Hic-5 binding to SZ.22-immunoprecipitates from resting platelet lysates. However, we found 
this result difficult to replicate when we reversed the order of immunoprécipitation and used a 
Hic-5 antibody as the immunoprecipitating antibody. It is possible that the interaction of Hic-
5 and am, is transient and thus difficult to capture in our experiments. We found that the 
proteins PKARla and PINCH-1 belong to protein “W” characteristics, as they do not bind to 
the integrin at all. In addition, Hic-5 protein shows that it belongs either to protein “X” group 
when it binds to the resting integrin or belongs to protein “Z”, a protein that binds to the 
integrin regardless of its activation states.
We have faced a lot of challenges throughout the study that have been an advantage in 
gaining experimental skills. These challenges have been mentioned in the thesis and include; 
optimizing experimental procedures for western blotting; using the best type of beads 
according to the antibodies and handling the beads in co-IP experiments. Finally, we found 
that using different antibodies types whether they are monoclonal or polyclonal can influence 
the results.
Moreover, we found that Mass spectrometry analysis of the affinity interacting proteins has a 
percentage of error and different techniques should probably be used for optimum results. For 
example, the confocal results shown in chapter 4 can provide powerful support for 
immunoprécipitation data.
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Finally, due to the lack of time we could not increase the number of experiments to confirm 
the results. Thus, a future work includes more co-IP experiments with Hic-5 and analysis of 
SZ.22 can be a part of future project.
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Appendix
Lvsate : +  +  +  N o n  N o n  N o e  N og  N o n  N o n .
IP : N o n  N on  N o n  SZ.22 SZ.22 S Z.22 Ie G  Ie G  Ic G  .
Figure 4.1 (D) was adapted from this western blot. It presents an immunoprécipitation with 
SZ.22 antibody and western blot with Hic-5(H75) antibody.
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